Xcout IntelRege Nephro competitors & alternatives
The 12 closest competitors and alternatives to Rege Nephro among drug discovery companies — ranked by similarity to what Rege Nephro actually does, not by market-cap band.
Subscribe to see Rege Nephro’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Rege Nephro
Rege Nephro Co., Ltd. is a biotechnology company headquartered at Kyoto University in Kyoto, Japan. The company engages in medical-pharmaceutical collaborative research and advanced therapeutic development for kidney and regenerative medicine.
Rege Nephro at a glance
Rege Nephro is a drug discovery company headquartered in Japan. It has raised at least $77M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $62M in July 2026. Xcout tracks 15 named people at Rege Nephro, including Akifumi Morinaka (Representative Director and CEO).
Rege Nephro leadership
- Akifumi MorinakaRepresentative Director and CEO
- 山口 勝久取締役/CFO 管理本部長
- 森中 紹文代表取締役CEO
- 長船 健二最高科学顧問（創設者） 京都大学iPS細胞研究所教授
- 中野 毅執行役員 研究開発本部長
- 小林 義史執行役員 生産本部長
9 more named people on record for Rege Nephro, with roles, board committees and tenure — see the full roster →
Rege Nephro funding rounds
At least $77M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $62M | 14 named | |
| Series B | $15M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Rege Nephro competitors
Ranked by semantic similarity — how close each company is to Rege Nephro by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar drug discovery company
Kringle Pharma, Inc. is a late-stage regenerative drug discovery bio-venture located in Shinsenrihigashimachi, Osaka, Japan. The company operates in the biotechnology and manufacturing sectors.
Similar drug discovery company
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
Similar drug discovery company
iRegene Therapeutics is a biotechnology company headquartered in Wuhan, China, with additional facilities in Suzhou. The firm specializes in regenerative medicine and advanced cell therapies designed to redefine modern medicine.
Similar drug discovery company
Alebund Pharmaceuticals is a biopharmaceutical company founded in early 2018 in Shanghai, China, with operations also in Yangzhou City, focusing on the discovery and development of treatments for kidney disease.
Similar drug discovery company
Cellusion Inc. is a regenerative medicine company headquartered in Chuo, Tokyo, Japan. The company focuses on regenerating human potential and maintains its headquarters in the Nihonbashi-Harumi area to foster close community and business connections.
Similar drug discovery company
Sarcomatrix Therapeutics Corp. is a biopharmaceutical and biotechnology research company headquartered in Reno, Nevada. The company is dedicated to pioneering muscle regeneration therapies and advancing novel therapeutics to treat muscle-wasting diseases.
Similar drug discovery company
Gero is a biotechnology company headquartered in Singapore with a U.S. subsidiary, combining physics, biology, and artificial intelligence to decode human biology and develop life-changing medicines.
Similar drug discovery company
Momotaro-Gene Inc. is a drug discovery company established in 2007 and headquartered in Okayama, Japan. The company focuses on pharmaceutical research and the development of next-generation cancer therapeutics.
Similar drug discovery company
Renasis Bio Ltd. is a stealth-mode private company headquartered in Rehovot, Israel, established in 2025. The firm is developing an AI-driven drug discovery platform focused on RNA-targeting small molecules to advance RNA druggability.
Similar drug discovery company
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Biopharmaceuticals
PharmaResearch is a pharmaceutical biotechnology company based on regenerative medicine, dedicated to enhancing the quality of human life and headquartered in South Korea.
Biopharmaceuticals
Kyoto Drug Discovery and Development is a Japanese bioventures startup founded in April 2015. The company specializes in pharmaceutical research and the development of novel therapeutics such as VCP modulators.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Rege Nephro and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Rege Nephroand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →